Medpace is delivering strong bookings, backlog growth, and raised 2026 guidance, but the stock already reflects a premium multiple. TickerSpark rates it Hold as valuation tempers an otherwise high-quality operating profile.
Medpace Holdings (MEDP) is a high-quality clinical research organization with strong growth, exceptional cash generation, and a clean balance sheet. The investment case rests on three hard facts: Q2 2026 revenue rose 17.2% to $707.3M, net new business awards increased 28.2% to $795.7M, and ending backlog reached approximately $3.0B. The counterweight is valuation. MEDP trades at 36.3x trailing earnings, 31.9x forward earnings, and 2.9x PEG, while the analyst consensus is Hold with a $595.92 target.
The medium-term setup is constructive but does not justify chasing the stock at any price. Management raised 2026 guidance to $2.805B to $2.885B of revenue and $17.25 to $17.95 of diluted EPS. The company also reported a 1.13x net book-to-bill ratio in Q2 and projected that $1.96B of backlog will convert to revenue over the following 12 months. Those figures support continued earnings growth, but the current valuation already prices MEDP as a premium operator.
The recommendation is Hold for a moderate-risk investor with a medium-term horizon. MEDP has the operating profile of a compounder, but the share price requires sustained execution across bookings, backlog conversion, staffing, and biotech funding. A pullback toward the $550 area would improve the risk-reward profile materially.
Medpace Holdings is a Cincinnati-based, NASDAQ-listed contract research organization founded in 1992. The company employs approximately 6,500 people and provides clinical development services across North America, Europe, Asia, South America, Africa, and Australia. Its offering spans Phase I through Phase IV trials for pharmaceutical, biotechnology, and medical-device customers.
The service portfolio covers project design, clinical monitoring, regulatory affairs, data management, statistical analysis, pharmacovigilance, medical writing, central laboratory work, bioanalysis, imaging, electrocardiography, and post-marketing support. Medpace reports as one operating segment, reflecting an integrated full-service model rather than a portfolio of separately managed divisions.
Revenue is recognized as work progresses under fixed-fee or unit-of-service contracts. The 2025 10-K states that most contracts contain a single performance obligation and that progress is generally measured using a cost-to-cost method. That accounting model links reported revenue to study execution, estimated costs, project scope, and customer decisions. It also explains why backlog is useful but cannot be treated as a guaranteed sales figure.
Although MEDP has one reportable operating segment, its therapeutic mix provides a meaningful view of the business. 2025 revenue included $747.6M from Oncology, $745.0M from Metabolic, $254.8M from Central Nervous System, $239.4M from Cardiology, $134.9M from Antiviral and Anti-Infective programs, and $408.5M from Other areas.
The mix changed sharply from 2024. Metabolic revenue rose from $457.5M to $745.0M, while Central Nervous System revenue increased from $182.0M to $254.8M. Oncology remained the largest reported therapeutic area at $747.6M, compared with $651.2M in 2024. The concentration in Metabolic created a powerful growth engine, but it also increased exposure to a narrower group of large programs.
Q2 2026 marked a shift in the booking mix. Management said Oncology represented more than half of overall bookings and award notifications, while new Metabolic and cardiometabolic opportunities had declined from the prior year. That rotation gives MEDP a broader therapeutic foundation, although Oncology trials can have longer timelines and more decision points before revenue is recognized.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
MEDP's flagship product is its integrated clinical development platform. Rather than selling a single drug, instrument, or software license, the company sells execution across the development lifecycle. Sponsors can use Medpace for study design, patient recruitment, clinical operations, laboratory services, data analysis, regulatory work, and post-marketing support.
The platform's commercial proof appears in the backlog and booking data. Q2 net new business awards reached $795.7M, up 28.2% year over year, with a 1.13x net book-to-bill ratio. Ending backlog stood at approximately $3.0B, up 4.9% year over year, and management expects approximately $1.96B to convert into revenue over the next 12 months.
The platform also benefits from embedded operational knowledge. Medpace works across Phase I to Phase IV studies and multiple therapeutic areas, allowing experience from oncology, metabolic, CNS, and cardiology programs to reinforce its delivery model. The principal product risk is execution complexity: customer cancellations, scope changes, trial delays, and cost estimates can alter both timing and profitability.
Medpace's competitive advantage is operational rather than dependent on a single proprietary technology. The company combines therapeutic specialization, full-service coverage, global trial execution, and a stated focus on timely and cost-effective delivery. The 2025 10-K identifies the cost and experience required to build therapeutic expertise, manage global studies, recruit investigators and patients, and prepare regulatory submissions as barriers to entry.
Q2 operating data supports the effectiveness of that model. Management reported that RFPs were up substantially both sequentially and year over year, with improved quality. It also said changes made after a weaker 2025 win rate were in place and may have influenced the strong Q1 2026 win rate. Q2 initial award notifications declined from a very strong Q1, but remained in a solid range.
Technology remains an important competitive filter. Medpace identifies artificial intelligence and cybersecurity as risk areas in its 10-K, while Deloitte reported that 41% of surveyed life sciences executives viewed generative AI as an influential trend shaping 2026 strategy. The available data supports a requirement for continued investment in digital trial workflows, but it does not establish a separate technology revenue stream for MEDP.
For a CRO, the most important supply-chain assets are scientific personnel, clinical sites, patient access, data systems, and regulatory capability. Management said employee growth has been concentrated in the United States and Asia-Pacific, including India, while total employee growth is expected to remain in the high single digits during 2026.
Staffing execution has been favorable. Management described turnover as very low on historical terms and said the company was in a good resource position relative to demand. That matters because a CRO can lose margin when it must fill urgent projects with expensive contractors or carry excess staff ahead of bookings.
Cash conversion was also strong in Q2. Operating cash flow reached $162.0M, while net days sales outstanding was negative 59.6 days. Medpace repurchased approximately 706,000 shares for $294.7M during the quarter and retained $527M under its share repurchase authorization as of June 30, 2026. That capital allocation supports per-share earnings, although large buybacks also explain part of the movement in cash.
The relevant market for MEDP is outsourced clinical research rather than the entire life sciences tools industry. Fortune Business Insights projects the global CRO services market to reach $199.28B by 2034 at a 9.0% compound annual growth rate. That market growth is supported by drug-development complexity, regulatory requirements, and the use of external providers by sponsors that do not want to build every clinical capability internally.
The broader life science tools market provides a second demand signal. Mordor Intelligence estimates that services are the fastest-growing segment of that market at an 11.35% CAGR. The trend favors providers that can combine operational expertise with data-heavy workflows, especially in oncology, rare disease, precision medicine, and advanced therapies.
MEDP is growing faster than the large CRO market averages in the current cycle. 2025 revenue increased 20.0% to $2.53B, and Q2 2026 revenue grew 17.2% year over year. The gap between company growth and market growth supports a premium multiple, but the premium requires Medpace to retain its booking momentum and avoid a sharp deterioration in sponsor funding.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Medpace has historically emphasized small and mid-sized biopharmaceutical customers. The 2025 customer mix included 82% of revenue from small biopharmaceutical companies and 13% from mid-sized biopharmaceutical companies. This positioning gives MEDP access to sponsors that need a full-service development partner rather than a narrow functional vendor.
The same customer profile creates funding sensitivity. Smaller biopharma companies depend more heavily on equity markets, venture funding, partnerships, and clinical milestones. Management said recent funding had become broader across clients and that the pipeline included more opportunities from recently funded companies. That statement aligns with the Q2 increase in RFPs and net awards.
Customer concentration deserves a permanent place in the risk model. The top five customers represented roughly 31% of last-twelve-month revenue in Q2, while the top ten represented approximately 40%. Management linked much of the top-five growth to large Metabolic programs. Concentration can accelerate growth when programs expand, but cancellations or funding problems at a few large sponsors can affect reported revenue.
Medpace competes with IQVIA (IQV), ICON (ICLR), Fortrea (FTRE), PPD within Thermo Fisher Scientific (TMO), specialty CROs, regional providers, and internal sponsor teams. IQVIA reported 2025 revenue of $16.31B, ICON reported $8.25B, and Fortrea reported $2.72B. MEDP's 2025 revenue of $2.53B places it near Fortrea in scale but with a more focused operating model.
The growth comparison favors MEDP. IQVIA's 2025 revenue rose 5.9%, while ICON's increased 0.8%, compared with MEDP's 20.0% revenue growth. Scale gives the larger competitors broader data assets, geographic coverage, and purchasing power. Medpace counters with therapeutic focus, an integrated model, and a customer profile that values speed and operational discipline.
Competition is based on more than price. Medpace's 10-K identifies therapeutic expertise, staff quality, reliability, investigator and patient recruitment, global execution, speed, and overall value as competitive factors. The company therefore needs to protect both service quality and employee retention as it expands. A premium valuation is defensible only while those operating advantages remain visible in bookings and margins.
The macro backdrop is mixed for MEDP. Outsourcing demand benefits from complex trials and disciplined sponsor spending, while small-biotech funding remains a direct variable for new awards. Management reported that cancellations declined substantially in Q2 and described the business environment as strong, but it also called cancellations a wild card that can arise without advance warning.
Geographic execution introduces foreign exchange, regulatory, labor, and data-governance exposure. The 2025 10-K identifies foreign currency, inflation, interest rates, and credit risk as market risks. Management said it did not see a significant shift of the programs it was pursuing toward China, reducing one specific geopolitical concern in the near term.
Tax policy is another cross-border consideration. Medpace recorded $8.3M of liabilities for uncertain tax positions at December 31, 2025 and continues to monitor the OECD Pillar Two framework and changes in U.S. tax legislation. Management's 2026 guidance assumes an effective tax rate of 19.0% to 19.5%, making tax execution relevant to the earnings outlook.
Medpace’s balance sheet earns an A- thanks to a clean capital structure and strong cash generation, giving it room to fund growth without balance-sheet strain.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q2 2026 revenue rose 17.2% to $707.3M and net new business awards jumped 28.2% to $795.7M, underscoring the company’s operating momentum.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management lifted 2026 revenue guidance to $2.805B-$2.885B and EPS guidance to $17.25-$17.95, signaling continued earnings growth ahead.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →MEDP trades at 36.3x trailing earnings, 31.9x forward earnings, and 2.9x PEG, leaving little margin for error at the current price.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →With an overall grade of B and a Hold recommendation, the report sees better risk-reward on a pullback toward $550 rather than at today’s premium valuation.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Medpace combines a strong operating model with unusually good financial execution. Q2 2026 revenue rose 17.2%, net new awards increased 28.2%, backlog reached approximately $3.0B, and operating cash flow reached $162.0M. The company also carries far more cash than quarterly debt and has maintained a seven-quarter EPS beat streak.
The risk is not business quality. It is the price paid for that quality. MEDP remains exposed to small-biotech funding, customer concentration, cancellations, trial timing, employee costs, and a shift in therapeutic mix. The $600 fair-value estimate captures the durable franchise without assuming that every favorable operating trend continues at peak speed.
For moderate-risk investors, Hold is the disciplined position. Existing shareholders have a profitable, cash-generative compounder with a credible 2026 and 2027 earnings path. New buyers have a better setup at $550 or below, where the balance sheet and backlog provide more protection against the inevitable periods when the clinical research business becomes less cooperative.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Medpace Holdings, Inc. (MEDP) rises after a Q3 earnings beat, but the deeper story is margin expansion, stronger bookings, and a growing backlog. This analysis goes beyond the headline to weigh guidance, segment mix, and what the latest quarter may signal for 2026.
Medpace Holdings, Inc. (MEDP) gains 4.4% after reporting earnings beats, as investors react positively to the latest quarterly results and outlook.
Pieter Slegers fronts Tiny Titans' Compounding Quality promotion, “The Hidden AI Healthcare Giant.” We trace the stock and test its AI claims.